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Background: Few guidelines focus on the preventive and maintenance care of infants with cystic fibrosis (CF). We explored how practice
variability at accredited CF centers affected nutritional outcomes.
Methods: A retrospective cohort study using Cystic Fibrosis Foundation registry data (1993–2004) from three CF centers compared the initial
management with respiratory, antimicrobial, and nutritional agents in infants. Further, we examined the association between dornase alpha use
prior to two years of age and BMI percentile over time accounting for several possible factors including gender, race, CF center, presentation, age
at diagnosis, sweat value, F508del status, first Pseudomonas aeruginosa infection age, second-year weight percentile, supplemental feedings use,
and pancreatic enzymes use.
Results: Patient characteristics and prescribed therapies were similar at all sites for 165 patients who met inclusion criteria. However, one CF
center prescribed dornase alpha significantly more frequently, 82% vs. 10% (pb0.001), and supplemental feeds significantly less frequently, 56%
vs. 78% (p=0.04). Dornase alpha prescription prior to age two was associated with a 10-percentile increase in BMI through age six compared to
infants not prescribed dornase alpha.
Conclusions: Treating infants less than two years old with dornase alpha may improve nutritional outcome through age six.
© 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Children 0–2 years old; Dornase alpha; Body mass index percentile1. Introduction
Increased newborn screening for cystic fibrosis (CF) [1,2]
leads to earlier diagnosis of children with CF and prompts
clinicians to develop management programs that address nutri-
tional, gastrointestinal, and pulmonary concerns of CF [3,4].
Malnutrition can occur as early as six weeks of age [5], and
airway changes (airway wall thickening and dilatation) as early
as four months of life [6,7]. Airway infection and inflammation⁎ Corresponding author. Division of Pulmonary Medicine, Alfred I. duPont
Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, United
States. Tel.: +1 302 651 6400; fax: +1 302 651 6408.
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1569-1993/$ - see front matter © 2008 Published by Elsevier B.V. on behalf of Euhave been recognized in children younger than three years of
age [8,9].
Evidence from observational and randomized studies
suggests that early diagnosis and treatment improve long-term
nutritional status and lung health [10–14]. Early introduction of
preventive therapy may slow diminishing nutritional status and
the progressive decline in lung function seen in patients with CF
[11]. Although a Cochrane review of four studies indicated that
early anti-staphylococcal antibiotic prophylaxis was associated
with fewer isolates of Staphyloccocus aureus, there was no
significant effect on patient nutrition, hospital admissions, or
number of Pseudomonoas aeruginosa isolates [15]. It has been
proposed that younger patients may benefit from dornase alpha
[16], but there is no consensus regarding the most appropriate
age to initiate this therapy [17–19] or other medications such as
high-dose ibuprofen [20,21] and macrolides [22,23].ropean Cystic Fibrosis Society.
Table 1
Baseline characteristics of study patients a
Characteristic Cohort CF Center 1 CF Center 2 CF Center 3
(n=165) (n=50) (n=51) (n=64)
Age at 1st visit, months 8.3 (7.3) 7.6 (6.7) 8.3 (7.6) 8.8 (7.7)
Age at diagnosis, months 4.9 (6.6) 6.0 (7.4) 5.5 (7.2) 3.6 (5.1)
Male, No. (%) 85 (51.5) 26 (52) 24 (47.1) 35 (54.7)
White race, No. (%) 155 (93.9) 45 (90) 48 (94.1) 62 (96.9)
Genotype, No. (%)
Homozygous F508del 87 (52.7) 25 (50.0) 27 (52.9) 35 (54.7)
Heterozygous F508del 48 (29.1) 13 (26.0) 11 (21.6) 24 (37.5)
Neither F508del allele 9 (5.5) 5 (10.0) 2 (3.9) 2 (3.1)
Missing genotype 21 (12.7) 7 (14.0) 11 (21.6) 3 (4.7)
a Data are given as mean (SD) except where noted.
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in developing and disseminating the Clinical Practice Guide-
lines for Cystic Fibrosis [24], but there are few age-specific
recommendations directed to children younger than two years.
Even when these guidelines provide recommendations for care,
practice patterns among CF centers vary [24,25]. Varying CF
center practice patterns have been associated with differences in
growth and lung function in patients older than six years [26].
The multispecialty group at Nemours cares for approximately
400 children at three CFF-accredited centers in Delaware and
Florida. We hypothesized that variability in our management of
children with CF younger than two years old would affect sub-
sequent nutritional status.
2. Methods
2.1. Study design and population
The CFF Patient Registry contains health information on
over 23,000 CF patients who receive care at CFF-accredited
centers [4,12]. Since 1990, the Nemours CF multispecialty
centers in Wilmington, DE; Orlando, FL; and Jacksonville, FL,
have submitted data to the CFF Registry.
In order to conduct a retrospective cohort study, we obtained
longitudinal data from the CFF Registry on children seen at
Nemours CF centers. The sampling frame consisted of children
seen at any Nemours CF center between January 1, 1993, and
December 31, 2004. To be eligible for inclusion, children were
required to have a CFF Registry entry when they were less than
two years of age. Of the 680 patients seen in this time period,
165 children met these criteria. Among these 165 eligible chil-
dren, there were 110 with at least four entries with height and
weight recorded after two years of age. We limited follow-upFig. 1. Profile plot of BMI percentile over time by dornase alpha use status.time through age nine years. The Nemours Institutional Review
Board (IRB) approved this study.
2.2. Data analysis
Baseline characteristics of study patients, their initial presen-
tation, and management with respiratory, antimicrobial, anti-
inflammatory, and nutritional agents when under two years old
were compared across Nemours centers. In addition to these
clinical measures, frequency of office visits and respiratory tract
cultures were assessed. Assessing nutritional status could have
utilized a variety of measurements including anthropometric
standards expressed as percentage, standardized score, or Z-
scores of the normal values for age and gender body mass index
(BMI) percentile, percentile ideal body weight, and rate of growth
[3,27]. We choose BMI percentile as an outcome measure based
on expert recommendations for surveillance [4,24,28].
To construct a longitudinal model predicting childhood BMI
percentile, the subgroup of patients (n=110) with at least four
entries with height and weight recorded after two years old was
selected. Of the ineligible 55 children, 23 were excluded
because they had fewer than four encounters with entries of both
height and weight during the observation period, and 32 be-
cause they had no information recorded following their second
birthday.
The analytical strategy for modeling the effect of management
on nutritional outcome involved a preliminary analysis to examine
the bivariate correlation between BMI percentile and potential
confounders, and visual assessment of profile plots of BMI
percentile vs. time (Fig. 1). We fitted a longitudinal general linear
mixedmodel using the PROCMIXEDprocedurewith a first order
autoregressive covariance structure [29,30]. We selected this
technique because of the longitudinal format of the data and
because our interest was to estimate the between-subject effect
over time. The following variables were considered for adjust-
ment: child's sex and race, CF center, initial clinical presentation
suggesting the diagnosis of CF, age at diagnosis, initial sweat
value, F508del status, age at first P. aeruginosa infection, last
weight percentile in the second year of life (analyzed instead of
BMI percentile due to age), and the use of supplemental feedings
and pancreatic enzymes before age two.
The BMI percentiles were computed using the SAS program
from the Centers for Disease Control and Prevention (CDC,
Table 2
Management of patients with cystic fibrosis (age≤2 years) a
All CF center 1 CF center 2 CF center 3 p
(n=165) (n=50) (n=51) (n=64)
Visits 7.0 (3.7) 7.7 (3.4) 6.7 (3.8) 6.7 (3.9) 0.27
Number of
respiratory tract
cultures obtained
per year, No. (%)
None reported 19 (11.5) 3 (6.0) 3 (5.9) 13 (20.3)
One 48 (29.1) 16 (32.0) 17 (33.3) 15 (23.4) 0.08
Two or more 98 (59.4) 31 (62.0) 31 (60.8) 36 (56.3)
a Data are given as mean (SD) except where noted.
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(Statistical Packages for the Social Sciences) version 12.0.1
(SPSS Inc., Chicago, IL) was used to perform the descriptive
analysis on the practice patterns. SAS version 9.1 (SAS Institute,
Cary, NC) was used for all other analyses.
3. Results
Of 680 patients seen at a Nemours CF Center during the 12-
year period (1993–2004), data from a final cohort of 165
meeting inclusion criteria were analyzed for overall manage-
ment patterns. Baseline characteristics among the cohort and
patients seen at each of the CF centers were similar (Table 1).
The mean age of diagnosis was 8.3 months and median time
span of follow-up 45 months. The most common presenting
symptoms at diagnosis were failure to thrive/malnutrition (44%)
and acute/persistent respiratory symptoms (38%). Family his-
tory was positive in 11%, and 8% had a suspicious neonatal
screen.
As shown in Table 2, there were no significant differences
among CF centers regarding number of patient visits during the
first two years of life. Among all CF centers, patients averaged
3.9 visits per year from 1993–1996 and, following the publication
of clinical practice guidelines in 1997, 4.8 visits per year, in-
dicating that centers adhered to CFF guidelines. Differences in the
number of respiratory tract cultures obtained by CF center were
not statistically significant (Table 2). Most patients were recom-
mended pancreatic enzymes and a minority prescribed episodic
aerosolized tobramycin with some variability among CF centersTable 3
Specific therapies prescribed to patients with cystic fibrosis (age≤ two years) a
Therapy All CF center
(n=165) (n=50)
Dornase alpha 53 (32.1) 41 (82)
Nutritional supplements 114 (69.1) 28 (56)
Pancreatic enzymes 150 (90.9) 50 (100)
Episodic aerosolized tobramycin 29 (17.5) 14 (28)
Chronic aerosolized tobramycin 4 (2.4) 2 (4)
Ursodeoxycholic acid 4 (2.4) 2 (4)
Ibuprofen 0 0
a Data are given as number (%); N/A=no valid p-value available due to small ce(Table 3). The CF centers were dissimilar in their practice of
prescribing dornase alpha and recommending nutritional supple-
mentation to children under two years of age (Table 3).
3.1. Dornase alpha and nutritional status
Among the 110 children with at least four encounters with
height andweight recorded after two years of age, 35 (31.8%)were
treated with dornase alpha when under two years of age. All 35
(100%) patients treated with dornase alpha prior to the age of two
continued their dornase alpha in subsequent years. Of 75 (68.2%)
who did not receive dornase alphawhen under two years of age, 36
(48%) were eventually treated with dornase alpha at least once by
six years of age. Those patients treated with dornase alpha when
under two years of age were similar to those not using dornase
alpha, except that fewer patients received supplemental feedings
andmore used pancreatic enzymes (Table 4). Although there were
no differences in the frequency of respiratory tract cultures
between the CF centers (p=0.08), infants who developed P.
aeruginosa infection at a significantly earlier age were more likely
to have been treated with dornase alpha when under two years of
age (p=0.03). The effect of supplemental feeding before two years
of age on BMI percentile over time was evaluated for statistical
significance and its effect on the coefficient. When included in the
model, supplemental feeding was not significantly associated with
BMI percentile (p=0.12), and its effect on the coefficient was less
than 1%. Similarly, use of pancreatic enzymes did not significantly
contribute to the model, so both supplemental feeding and pan-
creatic enzyme use were excluded from the final model.
Our final model included dornase alpha, sex, sweat value, last
weight percentilemeasured during the second year of life, F508del
status, and initial clinical presentation. We found that early use of
dornase alpha was significantly associated with a higher BMI
percentile over time. Those patients treated with dornase alpha
when less than two years of age had a mean BMI percentile of
50.78 (SD 28.70) from age 2–3 years. Controlling for all other
variables in the model, children who received dornase alpha
before age two had an average BMI percentile that was 10.2
percentiles greater than children who did not. BMI percentile was
affected positively by last weight percentile in the second year of
life [(coefficient 0.39); (pb0.01)], and negatively by male gender
[(−4.5 percentiles); (p=0.07)], initial disease presentation (based
on the presence of positive family history, meconium ileus,1 CF center 2 CF center 3 p
(n=51) (n=64)
5 (9.8) 7 (10.9) b0.001
40 (78.4) 46 (71.9) 0.04
45 (88.2) 55 (85.9) 0.03
2 (3.9) 13 (20.3) b0.001
1 (2.0) 1 (1.6) N/A
0 2 (3.1) N/A
0 0 N/A
ll counts.
Table 4
Baseline characteristics of study subjects, by dornase alpha use status a
Covariate/confounder Dornase alpha
prescribed before
age two
Dornase alpha
not prescribed
before age two
p
(n=35) (n=75)
Male 20 (57.1) 38 (50.7) 0.53
White race 30 (85.7) 72 (96.0) 0.05
Site
CF center 1 28 (80.0) 9 (12.0) b0.001
CF center 2 3 (8.6) 31 (41.3)
CF center 3 4 (11.4) 35 (46.7)
F508del status
Homozygous F508del 16 (45.7) 37 (49.3) b0.001
Heterozygous F508del 9 (25.7) 28 (37.3)
Neither F508del allele 5 (14.3) 1 (1.3)
Missing genotype 5 (14.3) 9 (12.1)
Initial clinical presentation
Family history 4 (11.4) 12 (16.0) 0.47
Meconium ileus 8 (22.9) 27 (36.0)
Respiratory symptoms 16 (45.7) 23 (30.7)
Malnutrition 4 (11.4) 9 (12.0)
All others 3 (8.6) 4 (5.3)
Use of pancreatic enzymes 35 (100) 63 (84.0) 0.01
Supplemental feeding 19 (54.3) 60 (80.0) 0.01
Age at diagnosis, months,
mean (SD)
7.3 (6.9) 4.6 (6.4) 0.05
Initial sweat chloride, mg/dL,
mean (SD)
96.7 (25.5) 99.1 (15.3) 0.60
Age at 1st pseudomonas
infection, years, mean (SD)
2.3 (1.5) 3.6 (2.3) 0.03
Last weight percentile before
age 2 years, mean (SD)
28.0 (26.0) 29.7 (28.2) 0.77
a Data are given as number (%), except where noted.
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higher initial sweat value [(−0.44); (pb0.01)], and F508del status
(based on both, one, or neither alleles) [(−4.20); (p=0.03)].
4. Discussion
Over a 12-year period, three Nemours CF centers cared for
infants with similar characteristics and managed these young
children similarly, except for treatment with dornase alpha and
nutritional supplementation. Although statistically signifi-
cant, the clinical impact of the variability among CF centers
in pancreatic enzyme use and episodic aerosolized tobramycin
prescription appeared limited. Early treatment with dornase
alpha was associated with an increase in BMI percentile when
compared with those patients who were not prescribed dornase
alpha, although this observation does not necessarily indicate
causality. A previous study reported dornase alpha had no effect
on nutritional outcomes among older children (age 6–10 years)
[17]. Similarly, our cohort did not demonstrate a sustained
improvement in BMI percentile by early dornase alpha status
after six years of age (Fig. 1). However, this finding could be a
consequence of having fewer recorded observations for older
subjects. Nutritional supplementation was found not to sub-
stantially affect the association between dornase alpha and
nutritional status. We did not perform analyses to evaluatedifferences among those who received dornase alpha after two
years of age.
How dornase alpha affects nutritional status is unclear.
Dornase alpha has been associated with increased airway
patency in infants with CF [31], and it reduces air trapping in
children with mild CF lung disease [32]. It provides some anti-
inflammatory effects with reduction in neutrophils in bronch-
oalveolar lavage fluid and in exhaled nitrous oxide [33,34]. It
has been proposed that dornase alpha improves long-term lung
health by modulating matrix metalloproteases [35] and affecting
biofilm formation [36]. Perhaps through reducing the work of
breathing and inflammation in young children there is a residual
benefit to their later growth, at least in young childhood.
Some factors initially presumed to affect nutritional status
did not bear out in analysis. Fewer patients in the dornase
alpha group were treated with supplemental feeding when under
two years old. The use of these supplemental feedings appears
to be related to CF center, not disease presentation, and failed to
significantly contribute to BMI percentile. Despite earlier P.
aeruginosa infection, children who received dornase alpha
when less than two years old exhibited better growth. This
finding of early infection contrasts with a previous report
that indicated the cumulative prevalence of colonization with
pathogens, including S. aureus and P. aeruginosa, was less
among patients treated with dornase alpha [36,37]. Children in
the CF centers may have had colonization with P. aeruginosa
prior to initial treatment with dornase alpha. Lung disease in
children with CF is commonly accelerated after acquisition with
P. aeruginosa [38,39]. Further study is needed to clarify any
relationship between dornase alpha and earlier colonization
with P. aeruginosa.
4.1. Limitations
This study has limitations common to retrospective observa-
tional studies. The results are based on data abstracted from
clinical records by different informants and secondarily re-
corded into an online registry on a periodic basis. Therefore data
entry and measurement errors could affect the accuracy of the
dataset. The relationship described between dornase alpha and
BMI percentile may have been influenced by unmeasured or
unknown confounders. For example, we were unable to adjust
for certain demographics (child's insurance status and mother's
education) and certain clinical features (age at first methicillin
resistant S. aureus infection and use of oral antimicrobials).
Although the status of pancreatic sufficiency/insufficiency was
not available, 91% of patients were on pancreatic enzyme
therapy prior to two years of age. Because pancreatic enzyme
therapy correlates poorly with growth [40], we did not include
pancreatic enzyme use as a variable in modeling. The impact of
some factors may have been lost when measured broadly. For
example, the effect of varying daily quantities of specific
formulations of nutritional supplements could be concealed by
the simple result of presence or absence of supplemental
feedings. Despite these limitations, the association between
early use of dornase alpha and increased subsequent BMI
percentile persisted after controlling for other confounders.
389R. Padman et al. / Journal of Cystic Fibrosis 7 (2008) 385–3905. Conclusions
Variability among three Nemours CF centers demonstrates that
early interventionwith dornase alpha appears to provide nutritional
benefits. Indeed, administration of dornase alpha to children under
two years old showed a persistent 10 percentile increase in BMI
years later, after controlling for other important clinical variables.
Additional research is needed to determine which early interven-
tions during infancy promote appropriate nutritional status and
better lung health in older children and adults with CF.
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